Bimekizumab for treating active psoriatic arthritis: a single technology appraisal
Bimekizumab for treating active psoriatic arthritis: a single technology appraisal
This report is a critique of the company’s submission (CS) to NICE from UCB Pharma on the clinical effectiveness and cost effectiveness of bimekizumab for treating psoriatic arthritis. It identifies the strengths and weaknesses of the CS.
National Institute for Health and Care Excellence
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Chinnery, Fay
57bc237a-8d07-4af1-b469-e801dff5715b
Picot, Joanna
324d6f20-a105-49fd-9fb0-88791be84ada
4 October 2023
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Chinnery, Fay
57bc237a-8d07-4af1-b469-e801dff5715b
Picot, Joanna
324d6f20-a105-49fd-9fb0-88791be84ada
Scott, David Alexander, Pickett, Karen, Cooper, Keith, Chinnery, Fay and Picot, Joanna
(2023)
Bimekizumab for treating active psoriatic arthritis: a single technology appraisal
(Health Technology Assessment)
National Institute for Health and Care Excellence
83pp.
Record type:
Monograph
(Project Report)
Abstract
This report is a critique of the company’s submission (CS) to NICE from UCB Pharma on the clinical effectiveness and cost effectiveness of bimekizumab for treating psoriatic arthritis. It identifies the strengths and weaknesses of the CS.
This record has no associated files available for download.
More information
Published date: 4 October 2023
Identifiers
Local EPrints ID: 484620
URI: http://eprints.soton.ac.uk/id/eprint/484620
PURE UUID: 07ca0ef2-61e1-4f06-b82a-8bc20dc2588c
Catalogue record
Date deposited: 17 Nov 2023 18:08
Last modified: 11 Sep 2024 02:26
Export record
Contributors
Author:
David Alexander Scott
Author:
Fay Chinnery
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics